PMCB
PharmaCyte Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.49
−0.98%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 391.3K | 391.3K | 438.4K | 407.4K | 468.5K |
| SG&A Expense | 4.9M | 4.9M | 3.9M | 6.1M | 4.8M |
| General & Admin Expense | 4.9M | 4.9M | 3.9M | 6.1M | 4.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.5M | 1.5M | — | 2.0M | 1.2M |
| Total Operating Expenses | 6.9M | 6.9M | 4.4M | 8.5M | 6.5M |
| Cost and Expenses | 6.9M | 6.9M | 4.4M | 8.5M | 6.5M |
| Operating Income (EBIT) | (6.9M) | (6.9M) | (4.4M) | (8.5M) | (6.5M) |
| Non-Operating | |||||
| Interest Income | 733.4K | 733.4K | 1.4M | 3.4M | 1.9M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 733.4K | 733.4K | 1.4M | 3.4M | 1.9M |
| Other Non-Op Income/Expense | (12.6M) | (12.6M) | 35.0M | 8.9M | 2.1M |
| Non-Operating Income (excl Interest) | (1.5M) | (1.5M) | — | (2.0M) | — |
| EBT (Pre-Tax Income) | (19.4M) | (19.4M) | 30.7M | 333.8K | (4.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (19.4M) | (19.4M) | 30.7M | 333.8K | (4.3M) |
| Earnings from Cont. Ops | (19.4M) | (19.4M) | 30.7M | 333.8K | (4.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (23.2M) | (23.2M) | 23.4M | (17.2M) | (4.3M) |
| Per Share | |||||
| Basic EPS | ($3.10) | ($2.77) | $3.19 | ($1.80) | ($0.22) |
| Diluted EPS | ($3.10) | ($2.77) | $3.19 | ($1.80) | ($0.22) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 9.6M | 7.0M | 7.3M | 185000 | 19.5M |
| Diluted Shares Outstanding | 10.7M | 8.4M | 7.3M | 9.6M | 19.5M |
| Profitability Metrics | |||||
| EBITDA | (5.3M) | (5.3M) | (4.4M) | (6.5M) | (6.5M) |
| D&A | — | — | — | — | — |
| EBIT | (5.3M) | (5.3M) | (4.4M) | (6.5M) | (6.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Apr 1, 2026